Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

Natriuretic Peptide System

Download as ppt, pdf, or txt
Download as ppt, pdf, or txt
You are on page 1of 30

Natriuretic Peptide System

Ri 黃敬淳/P 柯文哲
History
 1981, de Bold et al. first reported a potent
diuretic and natriuretic factor in rat atrial
extracts
 1984, Kangawa et al. identified atrial natriuretic
peptide (ANP)
 1988, B-type or brain natriuretic peptide (BNP)
 1990, C-type natriuretic peptide (CNP)
 Natriuretic peptide family: ANP, BNP, CNP,
DNP(dendroaspis), Urodilatin
 Shares a common 17-amino acid disulfide ring
Molecular biology - ANP
 28 a.a peptide hormone
 Produced primarily in the cardiac
atria
 Some is produced by ventricular
tissue of fetus, neonate and
hypertrophy
 Increased atrial-wall tension,
increased intravascular volume, is
the dominant stimulus for its
release
 Several hormons and
neurotransmitters directly stimulate
the secretion of ANP
Molecular biology - BNP
 32 a.a peptide hormone
 Initially isolated from
porcine brain
 Primarily derived from the
cardiac ventricle
 Secreted primarily in
response to increasing
cardiac wall tension
ANP- burst- acute change of atrial pressure
BNP- gene- chronically increased pressure
Curr Probl Cardiol, December 2004
Molecular biology - CNP
 22 a.a peptide hormone
 Predominates in the central
nervous system, anterior
pituitary, kidney, vascular ,
and endothelial cells
 Believed to be an
endothelial derived peptide
participating in an
autocrine/paracrine role to
regulate vascular
structure and tone
Molecular biology – DNP, Urodilatin
 DNP: 38 a.a peptide hormone
 First isolated from the venom of
the green mamba snake
 Physiologic role in unclear

• Urodilatin: 32 a.a peptide


hormone
• Alternative processing of the
ANP precursor in the kidney
• Intrarenal paracrine regulator of
sodium and water homeostasis
• Secreted into the distal nephron
to exerts its effects in the
medullary collecting duct
Most effects of the NPs are mediated through binding to NP receptors, which activate
particulate guanylyl cyclase and produce the second messenger, cyclic guanosine
monophosphate (cGMP)
The New England Journal of medicine Volume 339 Number 5, 1998
Cardiovascular Effects
•Increase venous capacitance
•Promotes natriuresis in kidney Reduce cardiac preload
•Suppresion of RAA system

Reflex tachycardia
Lower the activation threshold and vasocontriction
of vagal afferent

Suppress the release


of catecholamine from
Dampen baroreceptors autonamic nerve
ending
Renal Effects
1. Afferent renal arteriole  relaxation
GFR ↑
2. Efferent renal arteriole  constriction
3. Relax mesangial cell  surface area ↑
4. Production of Urodilatin  paracrine effect
5. Proximal tubule  Inhibit angiotensin Ⅱ
6. Cortical collecting duct  Antagonize vasopression
7. Medullary collecting ductBlock sodium absorption

Promote sodium and water excretion


Central Nervous System Effects

The actions of natriuretic peptides in brain


reinforce those in the periphery

• Inhibit salt appetite and water drinking


• Inhibit the secretion of vasopressin、corticotropin
• Act in the brain stem to decrease sympathetic
tone
The New England Journal of medicine Volume 339 Number 5, 1998
Anti-Remodeling Effects
•Inhibit the growth of cardiac fibroblast
•Retard the deposition of collage
•Induce cardiac myocyte aptosis

•Inhibit transforming growth factor (TGF-β) induced


fibrosis
•Limit the myocardial porliferative or hypertrophic
response to injury or ischemia

Anti-remodeling and Anti-fibrotic properties


NPs
NTG

•Randomized study in 60 patients with first anterior myocardial infarction


•Present with TIMI grade 0 or 1 by coronary angiography
•Prolong chest pain (>30min)+ ST elevation (>2mV, > 2 precordial leads) + successful infused (>24 hr.)
•Then all give ACEI(enalapril)
•Repeat cardiac catheterization one month later

Journal of the American College of Cardiology Vol. 37, No. 7, 2001


Clinical application of BNP in the
emergency diagnosis of heart
failure
Unloading of
high-pressure
baroceptors

The New England Journal of medicine August 19, 1998


Response of NPs to heart failure

1. Myocardial failure with hypertrophy


2. Stretching of the failing atrial and ventricular myocardium
3. Elevated plasma concentration of Angiotensin Ⅱ

Increased production of BNP 、 ANP

1. Catecholamines ↓ The concentrations are


2. Anigotensin Ⅱ ↓ correlated with the
3. Aldosterone ↓ extent of ventricular
4. Systemic vascular resistance ↓ dysfunction
5. Systemic volume ↓

Myocardial performace ↑
110±225 pg/ml
346±390 pg/ml
675±450 pg/ml

1. Total of 1586 p’t from seven sites enrolled from April 1999 ~ December 2000
2. Came to the emergency department with acute dyspnea
3. Exclude patient under 18 y/o, those whose dyspnea was clearly not
secondary to CHF, and those with AMI or renal failure
4. BNP was measured
5. The CHF was diagnosed by two independent cardiologists who were blind to
the result of BNP
The New England Journal of medicine Volume 347 July 18, 2002
The New England Journal of medicine Volume 347 July 18, 2002
Predictors of Congestive Heart Failure
 A major challenge of heart failure is timely and
accurate diagnosis
 The best clinical predictor of congestive heart
failure was as increased heart size on chest X-
ray (accuracy, 81%)
 Followed by a history of congestive
What heart
about failure
BNP?
(accuracy, 75%)
What is the best
 Rales found on physical examination (accuracy,
69%) cut-point?
 History of paroxysmal nocturnal dyspnea
(accuracy, 60%)
The New England Journal of medicine Volume 347 July 18, 2002
The New England Journal of medicine Volume 347 July 18, 2002
Cardiovasc Rev Rep 25(3):100-104, 2004
Thank You For Your Attension!!
Conclusion
 B-type natriuretic peptide levels by
themselves were more accurate than any
other finding in the history, physical
finding, or laboratory value in delineating
the cause of dyspnea
CLEVELAND CLINIC JOURNAL OF MEDICINE
VOLUME 70 • NUMBER 4 APRIL 2003
 Heart failure When dose BNP
 Pulmonary hypertension increase?
 Atherosclertic vascular disease

 Biomarker in patient with heart failure and other


cariovascular diasease
 Early warning system to help to identify patients at high
risk for cardiac events
 Recombinant ANP (carperitide) and BNP (nesiritide) are
useful for management of acutely decompensated HF
 Investigated for myocardial and renal protection in the
setting of cardiac surgery
Clinical application of
 Prevention of cardiac remodeling BNP
• Age
• Renal dysfunction BNP level ↑

• Women
• Obese BNP level ↓

You might also like